Guidance

How medicines, medical devices and clinical trials would be regulated if there’s no Brexit deal

Continuing human medicine, device and clinical trial regulation in the UK if we leave the EU with no deal.

• From: Department of Health and Social Care
• Published: 23 August 2018
• Last updated: 3 January 2019 — See all updates

This publication was withdrawn on 17 July 2019

This page has been replaced by ‘Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal’.

Documents

How medicines, medical devices and clinical trials would be regulated if there’s no Brexit deal

HTML

Details

If the UK leaves the EU with no deal, this would affect the regulation of:

• medicines
• medical devices
• clinical trials

We have published an updated guidance note, which is in response to a consultation on a no-deal scenario.

Published 23 August 2018
Last updated 3 January 2019 + show all updates

1. 3 January 2019

   Updated with a link to an updated guidance note, published in response to a consultation on a no-deal scenario.

2. 14 September 2018

   Updated to inform that the notices may sometimes apply to businesses and citizens in the EEA.

3. 23 August 2018

   First published.